Form 4: Director Sells UTHR Shares Under 10b5-1 Plan

United Therapeutics Director Jan Malcolm sold 50 shares of common stock for $482.98 per share under a pre-arranged 10b5-1 trading plan.

Summary

• Director Jan Malcolm of United Therapeutics Corp (UTHR) reported a sale of common stock.
• The transaction involved the disposition of 50 shares.
• The shares were sold at a price of $482.98 per share.
• The sale was executed on December 11, 2025.
• This transaction was conducted pursuant to a Rule 10b5-1 trading plan established on September 11, 2025.
• Following the sale, Jan Malcolm beneficially owns 470 shares of UTHR common stock directly.

Sentiment

Score: 5

Explanation: The sale was conducted under a Rule 10b5-1 trading plan, which typically indicates a pre-scheduled transaction for personal financial planning rather than a reaction to new company-specific information. While an insider sale, the pre-planned nature makes it neutral in terms of immediate sentiment impact.

Industry Context

This filing reports a routine insider transaction by a director, which is a common occurrence in publicly traded companies and does not inherently reflect broader industry trends or competitive dynamics.

Stakeholder Impact

• Shareholders may observe a director selling shares, but the pre-arranged 10b5-1 plan mitigates concerns about insider sentiment regarding the company's future prospects.

Key Dates

Recommendation

The transaction is a routine, pre-scheduled sale under a 10b5-1 plan, not indicative of new material information or a change in the company's fundamental outlook. Therefore, it does not provide a basis for altering an existing investment thesis.

Keywords

United Therapeutics, UTHR, Insider Trading, Form 4, Stock Sale, Director Transaction, 10b5-1 Plan, Jan Malcolm